Pfizer wins case to stop Teva selling generic Viagra in USA
Global pharmaceutical behemoth Pfizer (NYSE: PFE) revealed yesterday that it has prevailed in its patent infringement action against Teva Pharmaceuticals USA, a subsidiary of Israeli generic giant Teva (Nasdaq: TEVA), in the US District Court for the Eastern District of Virginia relating to its best-selling erectile dysfunction drug Viagra (sildenafil), which has annual sales in the USA of around $1 billion.
Commenting on the ruling, Judge Rebecca Beach Smith stated: “Teva has not shown by clear and convincing evidence that the patent is invalid.” Moreover, “there is utterly no evidence” to support Teva’s claim that Pfizer intentionally withheld documents from the US Patent and Trademark Office, she said.
Original patent was due to expire next year
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze